Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of secukinumab in relapsing multiple sclerosis
jRCT2080222132Phase 2
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in multiple sclerosis (MS) (4 arms), sponsored by Novartis.
02
Drugs
secukinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2080222132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222132.